Enliven (ELVN) CMO Helen Collins Sells Shares, Exercises Options

What Happened

• Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics (ELVN), exercised stock options to acquire 5,000 shares at $2.48 per share (cash outlay $12,400) and the filing also reports a derivative disposition of 5,000 shares at $0.00 (RSU-related). On the same day (Aug 17, 2026) she sold 3,900 shares at a weighted average price of $58.37 (proceeds $227,650) and 1,100 shares at a weighted average price of $59.35 (proceeds $65,281), for total sale proceeds of $292,931. The Form 4 was filed on Aug 19, 2026.

Key Details

• Transaction date: August 17, 2026; Form 4 filed August 19, 2026 (timely).
• Option exercise: 5,000 shares @ $2.48; total cost $12,400. Footnote F6 states the option was fully vested and exercisable.
• Derivative disposition: 5,000 shares reported at $0.00 (footnotes F2 and F5 indicate certain securities are RSUs).
• Market sales: 3,900 shares at weighted avg $58.37 (prices ranged $57.895–$58.84 per F3), and 1,100 shares at weighted avg $59.35 (prices ranged $58.985–$59.535 per F4); total proceeds $292,931.
• Trading plan: Transactions were effected under a Rule 10b5‑1 trading plan adopted Oct 19, 2025 (F1).
• Shares owned after transaction: Not specified in the excerpt provided.

Context

• The filing shows both an option exercise and same‑day sales. When exercises and sales occur together, that can effectively be a cashless exercise or the sale of vested RSUs; the filing lists an RSU-related derivative disposition at $0.00. These actions are common forms of insider liquidity and do not, by themselves, indicate the insider’s view on company prospects.